High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm
Highlight
– The HARVEST randomized, double‑blind trial (n=499) compared high‑dose oral rifampin (cumulative 35 mg/kg/day for 8 weeks) versus standard rifampin dosing (10 mg/kg/day) in adults with tuberculous meningitis (TBM).
– Six‑month mortality was 44.6% in the high‑dose group versus 40.7% in the standard‑dose group (HR 1.17; 95% CI 0.89–1.54; P=0.25), with no evidence of benefit from higher rifampin dosing.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.